TGA provisional approval of Roche COVID-19 treatment, casirivimab with imdevimab (Ronapreve)

TGA

18 October 2021 - The TGA has provisionally approved the use of the Roche combination therapy, casirivimab + imdevimab (Ronapreve) for the treatment and prevention of COVID-19 in specific target populations.

Ronapreve now has provisional approval for treating adults and adolescents aged 12 years and older and weighing at least 40 kg who do not require supplemental oxygen for COVID-19 and who are at increased risk of progressing to severe COVID-19.

Read TGA News

Michael Wonder

Posted by:

Michael Wonder